Get started
PIRAMAL ENTERPRISES LTDPIRAMAL ENTERPRISES LTDPIRAMAL ENTERPRISES LTD

PIRAMAL ENTERPRISES LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

PEL trade ideas

The overall outlook for Piramal Enterprises (NS:PIRA) Ltdthe daily chart, PEL ltd is moving in an impulse wave pattern. Wave 4 is completed near 1600 levels and now wave 5 is in progress. The stock had finally given breakout over its consolidation phase. Ichimoku cloud has given the indication of positive strength as prices have broken above the cloud in the previous trading session. as buying opportunity for a movrds 1850 and then 1890 levels as long as we seen At 2180.... Disclaimer: this is not SEBI Registered Investment Advisor, Investing and Trading in the stock market is subject to market risk.
NSE:PELLong
by tradingjourney21
1
pel Piramal Enterprise Limited (PEL) is one of India's large diversified companies with presence in Pharma, Financial Services and Healthcare Information Management. The Company's pharmaceutical business consists of manufacturing and sale of own and traded bulk drugs and formulations. Its Healthcare segment includes pharma solutions, critical care, consumer products and imaging. Its Financial Services segment includes wholesale lending, alternative asset management and investments in Shriram Group. Its Information Management segment is engaged in Decision Resources Group (DRG). DRG's product and services portfolio consists of data and analytics, research products and global consulting services. The Company offers its products under brands, including Saridon, Lacto Calamine, i-pill/i-know, Polycrol, Tetmosol, Untox, Stop AllerG and Throatsil. Over the last 2 years, the company has raised ~₹18,000 crore of equity as a result of which, its equity base increased by 29% and the net debt reduced by 45%. • It had an unallocated equity of ₹11,029 crore as on 31st March, 2021, which included investments in Shriram. • It also raised ₹33,478 crore of long term borrowings in the last 2 years which was utilized to repay most of its short term commercial paper borrowings. • It had a cash balance of ₹7,025 crore as on 31st March, 2021 which is ~15% of its loan book size. • The DHFL acquisition remains on track. It received the RBI (Reserve Bank of India) approval in February, 2021 and also the approval from the Competition Commission of India (CCI) was received in April, 2021. It is expected to be completed in the next few months. • DHFL acquisition fits well into the company’s overall retail strategy as it will enable it to achieve scale and leverage in the platform to cross-sell, significantly change its loan mix and lower its cost of borrowings. • The company is progressing towards transforming itself from a largely wholesale led NBFC (nonbanking financial companies) mostly focused on real estate, to a well-diversified one with the share Concall Summary PIRAMAL ENTERPRISES LIMITED of retail at 50% of the lending book in the near term from 12% as of March, 2021. This is done by undertaking three major strategies: Organic build-up of the retail lending business, completion of the DHFL acquisition and rationalising its wholesale portfolio to a more granular one. • During the year, Piramal Pharma Limited raised $490 million of fresh equity capital from the Carlyle Group for a 20% stake at an enterprise value (EV) of $2.7 billion. • In the complex hospital generics space, it completed the acquisition of Navin Flourine’s remaining 49% stake in convergence chemicals. • In Lodha, as on March, 2021, its exposure stood at ₹2,637 crore of which ~₹1,593 crore is in a SPV (special purpose vehicle) with a 1.5 times cover of fully ready inventory and the balance ~₹1,058 crore is in Macrotech Developers. It recently received a prepayment of ₹431 crore in the month of April, 2021, so its combined exposure has reduced to ₹2,150 crore. • In the CDMO business, it announced an investment of $32 million in its Riverview facility. • Real estate sector witnessed a revival in demand since October, 2020 driven by pent up in demand, changing customer preferences and Government initiatives. • Sales in the real estate segment are expected to fall in the month of May but collections for the company shall not be impacted to that extent. • Given the company has a strong order book and a lower base of FY21, the Pharma segment is expected to perform better in FY22. On a long term perspective, the management expects to maintain an organic growth of 15% for this business.
NSE:PELLong
by Tradernawab
PEL @ decisive level and high volatility next week PEL last friday closed at its support and formed a inside bar candle. Analysing carefully its formed Head & shoulder pattern, and respected the neckline which is also a strongest support to breach. Recent volume was higher than it's moving avg. volume Positive points: LTP trading above 50MA, and previous close. Volume was higher than previous volume. Narrow CPR, fraction less than Vwap, asking price is higher. Negative points: Trading at support, and technically week. RSI in oversold zone Next Week Forecast: It's Narrow CPR so the stock will become volatile once it's breach previous high/ low. If world market is positive and price is taking support at 1804 level (for aggressive trader), then can buy above 15 min opening range high and trailing the profit, if price moving strongly with volume support above 1832 safe trader can enter with trailing SL and aggressive trader can add more lots. If world market is negative and price is breaching support at 1804 level (for aggressive/ safe trader), then can sell below 15 min opening range high and trailing the profit, if price moving strongly with volume support below 1775 can add more lots for big moves. Disclaimer: THE RISK OF TRADING CAN BE SUBSTANTIAL AND EACH INVESTOR AND/OR TRADER MUST CONSIDER WHETHER THIS IS A SUITABLE INVESTMENT. PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. IT SHOULD NOT BE ASSUMED THAT THE METHODS, TECHNIQUES, OR INDICATORS PRESENTED IN THESE VIEWS WILL BE PROFITABLE OR THAT THEY WILL NOT RESULT IN LOSSES. PAST RESULTS ARE NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. VIEW PRESENTED ON THESE SITES ARE FOR EDUCATIONAL PURPOSES ONLY. THESE SET-UPS ARE NOT SOLICITATIONS OF ANY ORDER TO BUY OR SELL. THE AUTHORS, THE PUBLISHER, AND ALL AFFILIATES ASSUME NO RESPONSIBILITY FOR YOUR TRADING RESULTS. THERE IS A HIGH DEGREE OF RISK IN TRADING.
NSE:PEL
by jeetudixit
Piramal EnterprisesFor Short : Medium Term Buy on breakout of 2005.5 on higher volumes. SL1 : 1773.55 SL2 : 1178 TGT 1 : 2068.7 TGT 2 : 2558.35 +/- 2560 Additional Confirmation: Daily RSI (14) crossing up 70. - relative strength of price over 14 days. Daily Chaikin Money Flow : crossing .25, increase in price on higher volumes. Daily Stochastic : (i) Fast Stochastic crossing up Slow Stochastic. (ii) Fast Stochastic crossing below 80 and back. (iii) Waiting for oversold conditions on the stochastic (below 20) Daily MACD : Currently bullish. One can wait for a correction and a bullish crossover. IMO, the chart has already begun its next leg and if the other indicators do confirm the movement, it is unlikely to correct much further in the near future. This would likely mean, that some of the indicators mentioned above will not provide the necessary crossover and confirmation in the near future and will continue their present course. Volume however, is something that would be important to look out for. Lastly, this is not any indication of the fundamental value of the stock. * Not investment advice and I own some of this stock.
NSE:PELLong
by shutterdrug
2